MedTrace Logo

Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection

NCT02443935 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-06-29

No results posted yet for this study

Summary

Combination antiretroviral treatment (cART) effectively suppresses virus replication and partially restores immune functions. However, cART cannot cure HIV infection.

This study aim to investigate whether the antiviral immune response can be enhanced and/or viral transcription reactivated with MGN1703. MGN1703 is an agonist to toll-like receptor (TLR) 9. Activation of TLR9 has been shown to augment innate and adaptive immune effector functions, most notably enhanced NK cell and T cell functions.

Furthermore, TLR9 agonists have been shown in vitro to reactivate viral transcription in latently infected cells, potentially leading to enhanced recognition of infected cells by the immune effector cells.

Conditions

Interventions

DRUG

MGN1703

60 mg s.c. twice weekly for 4 weeks

DRUG

MGN1703

60 mg s.c. twice weekly for 24 weeks

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lars J Østergaard, MD,PhD,DMSc · Department for Infectious Diseases, Aarhus University Hospital, Denmark

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-06-01
Completion
2017-06-25

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02443935 on ClinicalTrials.gov